AMD and Celestica partner on Helios rack-scale Artificial Intelligence platform

AMD and Celestica are working together to bring the Helios rack-scale Artificial Intelligence platform to market. The effort combines AMD compute technology with Celestica networking switch development for large-scale clusters.

AMD and Celestica announced a strategic collaboration to bring the new Helios rack-scale Artificial Intelligence platform to market. The partnership combines AMD’s computing portfolio with Celestica’s expertise in data center infrastructure and networking switch technologies.

At launch, Celestica will undertake the R&D, design and manufacturing of scale-up networking switches in the AMD Helios rack-scale Artificial Intelligence architecture, based on the Open Compute Project (OCP), Open-Rack-Wide (ORW) form-factor. The companies position the effort around an open standards-based design for rack-scale deployment.

The scale-up switches will utilize advanced networking silicon to enable the high-speed interconnect of the next-generation AMD Instinct MI450 Series GPUs, enabling leading-edge computing, optimized for large-scale Artificial Intelligence clusters. The networking switches will utilize the Ultra Accelerator Link over Ethernet (UALoE) architecture for scale-up connectivity. AMD Helios will be available to customers in late 2026.

55

Impact Score

Governance gaps emerge as agentic Artificial Intelligence scales

Agentic Artificial Intelligence is moving from assisted chatbots to autonomous workflows faster than enterprise governance is adapting. The shift raises accountability, security, lifecycle, and cost control challenges that organizations must address in operational code from the start.

Where OpenAI technology could appear in Iran

OpenAI’s Pentagon deal and defense partnerships could place its models in targeting workflows, drone defense systems, and military administration tied to the Iran conflict. The company’s role reflects a broader push to weave generative Artificial Intelligence into US military operations.

Artificial Intelligence tumour testing aims to personalize cancer treatment

A UK-funded cancer testing platform is using living tumour replicas and Artificial Intelligence analysis to identify which drugs are most likely to work before treatment starts. Researchers say the approach could reduce ineffective chemotherapy and improve decisions for patients with aggressive cancers.

Contact Us

Got questions? Use the form to contact us.

Contact Form

Clicking next sends a verification code to your email. After verifying, you can enter your message.